Gerald J Atkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3891393/publications.pdf

Version: 2024-02-01

38742 54911 7,843 142 50 84 citations g-index h-index papers 149 149 149 9293 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A semiautomated method to quantitatively assess osteolytic lesion volume and bone mineral density within acetabular regions of interest from CT. Journal of Orthopaedic Research, 2022, 40, 396-408.	2.3	2
2	EMG-Informed Neuromusculoskeletal Models Accurately Predict Knee Loading Measured Using Instrumented Implants. IEEE Transactions on Biomedical Engineering, 2022, 69, 2268-2275.	4.2	21
3	Elevated levels of active Transforming Growth Factor \hat{l}^21 in the subchondral bone relate spatially to cartilage loss and impaired bone quality in human knee osteoarthritis. Osteoarthritis and Cartilage, 2022, 30, 896-907.	1.3	6
4	Long-Term Outcomes of Staged Revision Surgery for Chronic Periprosthetic Joint Infection of Total Hip Arthroplasty. Journal of Clinical Medicine, 2022, 11, 122.	2.4	7
5	Does Time to Theatre Affect the Ability to Achieve Fracture Reduction in Tibial Plateau Fractures?. Journal of Clinical Medicine, 2022, 11, 138.	2.4	3
6	A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 Gene. Calcified Tissue International, 2022, 111, 430-444.	3.1	2
7	Assigning trabecular bone material properties in finite element models simulating the pelvis before and after the development of peri-prosthetic osteolytic lesions. Journal of the Mechanical Behavior of Biomedical Materials, 2022, 133, 105311.	3.1	O
8	Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding. Biomolecules, 2022, 12, 960.	4.0	5
9	Postoperative lower limb joint kinematics following tibial plateau fracture: A 2-year longitudinal study. Gait and Posture, 2021, 83, 20-25.	1.4	7
10	Vitamin D supplementation improves bone mineralisation independent of dietary phosphate in male X-linked hypophosphatemic (Hyp) mice. Bone, 2021, 143, 115767.	2.9	8
11	Relationships between the Bone Expression of Alzheimer's Disease-Related Genes, Bone Remodelling Genes and Cortical Bone Structure in Neck of Femur Fracture. Calcified Tissue International, 2021, 108, 610-621.	3.1	8
12	Advancing of Additive-Manufactured Titanium Implants with Bioinspired Micro- to Nanotopographies. ACS Biomaterials Science and Engineering, 2021, 7, 441-450.	5.2	30
13	Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23. Calcified Tissue International, 2021, 109, 66-76.	3.1	25
14	Vitamin D receptor expression in mature osteoclasts reduces bone loss due to low dietary calcium intake in male mice. Journal of Steroid Biochemistry and Molecular Biology, 2021, 210, 105857.	2.5	6
15	Cognitive decline is associated with an accelerated rate of bone loss and increased fracture risk in women: a prospective study from the Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research, 2021, 36, 2106-2115.	2.8	14
16	A Human Osteocyte Cell Line Model for Studying Staphylococcus aureus Persistence in Osteomyelitis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 781022.	3.9	11
17	Generation of two multipotent mesenchymal progenitor cell lines capable of osteogenic, mature osteocyte, adipogenic, and chondrogenic differentiation. Scientific Reports, 2021, 11, 22593.	3.3	8
18	Evidence for Gender-Specific Bone Loss Mechanisms in Periprosthetic Osteolysis. Journal of Clinical Medicine, 2020, 9, 53.	2.4	5

#	Article	IF	Citations
19	Current Concepts of Osteomyelitis. American Journal of Pathology, 2020, 190, 1151-1163.	3.8	61
20	A New Approach to Surgical Management of Tibial Plateau Fractures. Journal of Clinical Medicine, 2020, 9, 626.	2.4	8
21	3D Bioprinting of Methylcellulose/Gelatin-Methacryloyl (MC/GelMA) Bioink with High Shape Integrity. ACS Applied Bio Materials, 2020, 3, 1815-1826.	4.6	83
22	Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS ONE, 2019, 14, e0222602.	2.5	17
23	Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways. Acta Biomaterialia, 2019, 87, 296-306.	8.3	41
24	The Late Osteoblast/Preosteocyte Cell Line MLO-A5 Displays Mesenchymal Lineage Plasticity <i>In Vitro</i> and <i>In Vivo</i> . Stem Cells International, 2019, 2019, 1-10.	2.5	4
25	Elevated Serum 25-Hydroxyvitamin D Levels Are Associated with Improved Bone Formation and Micro-Structural Measures in Elderly Hip Fracture Patients. Journal of Clinical Medicine, 2019, 8, 1988.	2.4	11
26	Surgical Technique to Manage Periprosthetic Fractures of the Knee in Patients with Infected Leg Ulcers. JBJS Case Connector, 2019, 9, e0347-e0347.	0.3	0
27	Novel Insights into Staphylococcus aureus Deep Bone Infections: the Involvement of Osteocytes. MBio, 2018, 9, .	4.1	114
28	Micro- and nano-structured 3D printed titanium implants with a hydroxyapatite coating for improved osseointegration. Journal of Materials Chemistry B, 2018, 6, 3136-3144.	5.8	62
29	Both ligand and VDR expression levels critically determine the effect of $1\hat{1}\pm,25$ -dihydroxyvitamin-D3 on osteoblast differentiation. Journal of Steroid Biochemistry and Molecular Biology, 2018, 177, 83-90.	2.5	13
30	Absence of vitamin D receptor in mature osteoclasts results in altered osteoclastic activity and bone loss. Journal of Steroid Biochemistry and Molecular Biology, 2018, 177, 77-82.	2.5	17
31	Evidence for altered osteoclastogenesis in splenocyte cultures from VDR knockout mice. Journal of Steroid Biochemistry and Molecular Biology, 2018, 177, 96-102.	2.5	1
32	A Fluorometric Method for the Quantification of Cell Number in Complex Differentiating Osteoblast-Osteocyte Cultures. Methods and Protocols, 2018, 1, 14.	2.0	0
33	Time dependent loss of trabecular bone in human tibial plateau fractures. Journal of Orthopaedic Research, 2018, 36, 2865-2875.	2.3	4
34	Vitamin D Activities in Osteocytes., 2018,, 319-327.		0
35	Postoperative weight bearing and patient reported outcomes at one year following tibial plateau fractures. Injury, 2017, 48, 1650-1656.	1.7	24
36	Anodized 3D-printed titanium implants with dual micro- and nano-scale topography promote interaction with human osteoblasts and osteocyte-like cells. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 3313-3325.	2.7	88

#	Article	IF	CITATIONS
37	Anticancer efficacy of the hypoxiaâ€activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Medicine, 2017, 6, 2164-2176.	2.8	9
38	Peroxidase enzymes inhibit osteoclast differentiation and bone resorption. Molecular and Cellular Endocrinology, 2017, 440, 8-15.	3.2	14
39	Adoptive transfer of exÂvivo expanded Vγ9VÎ 2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Letters, 2017, 386, 141-150.	7.2	24
40	Drug diffusion, integration, and stability of nanoengineered drugâ€releasing implants in bone <i>exâ€vivo</i> . Journal of Biomedical Materials Research - Part A, 2016, 104, 714-725.	4.0	32
41	Comparison of the biological effects of exogenous and endogenous 1,25-dihydroxyvitamin D3 on the mature osteoblast cell line MLO-A5. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 374-378.	2.5	4
42	Isolation of osteocytes from human trabecular bone. Bone, 2016, 88, 64-72.	2.9	35
43	Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy. Molecular Genetics and Metabolism, 2016, 119, 249-257.	1.1	13
44	Drug-releasing nano-engineered titanium implants: therapeutic efficacy in 3D cell culture model, controlled release and stability. Materials Science and Engineering C, 2016, 69, 831-840.	7.3	53
45	Anticancer efficacy of the hypoxiaâ€activated prodrug evofosfamide (THâ€302) in osteolytic breast cancer murine models. Cancer Medicine, 2016, 5, 534-545.	2.8	27
46	Evidence for altered osteoclastogenesis in splenocyte cultures from Cyp27b1 knockout mice. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 353-360.	2.5	8
47	Early response of the human SOST gene to stimulation by $1\hat{l}_{\pm}$,25-dihydroxyvitamin D3. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 369-373.	2.5	14
48	Osteocytes: The master cells in bone remodelling. Current Opinion in Pharmacology, 2016, 28, 24-30.	3.5	170
49	Evidence that osteocyte perilacunar remodelling contributes to polyethylene wear particle induced osteolysis. Acta Biomaterialia, 2016, 33, 242-251.	8.3	57
50	Peroxidase Enzymes Regulate Collagen Biosynthesis and Matrix Mineralization by Cultured Human Osteoblasts. Calcified Tissue International, 2016, 98, 294-305.	3.1	12
51	Sex-related differences in the skeletal phenotype of aged vitamin D receptor global knockout mice. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 361-368.	2.5	14
52	Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss. Acta Biomaterialia, 2016, 30, 311-318.	8.3	17
53	Skeletal characterization of an osteoblast-specific vitamin D receptor transgenic (ObVDR-B6) mouse model. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 331-336.	2.5	12
54	Nanoengineered drug releasing aluminium wire implants: a model study for localized bone therapy. Journal of Materials Chemistry B, 2015, 3, 3288-3296.	5.8	14

#	Article	IF	CITATIONS
55	Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters, 2015, 357, 160-169.	7.2	42
56	$1\hat{l}\pm,25$ -dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Molecular and Cellular Endocrinology, 2015, 413, 157-167.	3.2	43
57	Impaction bone grafting has potential as an adjunct to the surgical stabilisation of osteoporotic tibial plateau fractures: Early results of a case series. Injury, 2015, 46, 1089-1096.	1.7	14
58	A Role for the Calcitonin Receptor to Limit Bone Loss During Lactation in Female Mice by Inhibiting Osteocytic Osteolysis. Endocrinology, 2015, 156, 3203-3214.	2.8	47
59	Titania Nanotubes for Local Drug Delivery from Implant Surfaces. Springer Series in Materials Science, 2015, , 307-355.	0.6	19
60	Localized drug delivery of selenium (Se) using nanoporous anodic aluminium oxide for bone implants. Journal of Materials Chemistry B, 2015, 3, 7090-7098.	5.8	22
61	Nanoengineered drug-releasing aluminium wire implants: comparative investigation of nanopore geometry, drug release and osteoblast cell adhesion. RSC Advances, 2015, 5, 75004-75014.	3.6	6
62	1,25-Dihydroxyvitamin D3 and extracellular calcium promote mineral deposition via NPP1 activity in a mature osteoblast cell line MLO-A5. Molecular and Cellular Endocrinology, 2015, 412, 140-147.	3.2	24
63	Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Molecular and Cellular Endocrinology, 2015, 399, 208-218.	3.2	148
64	First Australian report of vitamin Dâ€dependent rickets type I. Medical Journal of Australia, 2014, 201, 420-421.	1.7	3
65	Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. International Journal of Oncology, 2014, 45, 532-540.	3.3	20
66	Osteoblast-Chondrocyte Interactions in Osteoarthritis. Current Osteoporosis Reports, 2014, 12, 127-134.	3.6	122
67	Osteocyte Communication with the Kidney Via the Production of FGF23: Remote Control of Phosphate Homeostasis. Clinical Reviews in Bone and Mineral Metabolism, 2014, 12, 44-58.	0.8	11
68	Vitamin D receptor overexpression in osteoblasts and osteocytes prevents bone loss during vitamin D-deficiency. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 128-131.	2.5	33
69	The local production of 1,25(OH)2D3 promotes osteoblast and osteocyte maturation. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 114-118.	2.5	44
70	Analysis of vitamin D metabolism gene expression in human bone: Evidence for autocrine control of bone remodelling. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 110-113.	2.5	23
71	SaOS2 Osteosarcoma Cells as an In Vitro Model for Studying the Transition of Human Osteoblasts to Osteocytes. Calcified Tissue International, 2014, 95, 183-193.	3.1	97
72	Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Anticancer Research, 2014, 34, 7007-20.	1.1	3

#	Article	IF	CITATIONS
73	Extracellular phosphate modulates the effect of $1\hat{l}_{\pm}$,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 183-186.	2.5	51
74	Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management. Inflammopharmacology, 2013, 21, 389-396.	3.9	35
75	Modulation of osteoclastic migration by metabolism of 25(OH)-vitamin D3. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 59-61.	2.5	14
76	Calcium induces pro-anabolic effects on human primary osteoblasts associated with acquisition of mature osteocyte markers. Molecular and Cellular Endocrinology, 2013, 376, 85-92.	3.2	27
77	Critical role of p38 MAPK for regeneration of the sciatic nerve following crush injury in vivo. Journal of Neuroinflammation, 2013, 10, 1.	7.2	131
78	The pleiotropic effects of vitamin D in bone. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 190-194.	2.5	55
79	Sclerostin Regulates Release of Bone Mineral by Osteocytes by Induction of Carbonic Anhydrase 2. Journal of Bone and Mineral Research, 2013, 28, 2436-2448.	2.8	130
80	The Paired-box Homeodomain Transcription Factor Pax6 Binds to the Upstream Region of the TRAP Gene Promoter and Suppresses Receptor Activator of NF-κB Ligand (RANKL)-induced Osteoclast Differentiation. Journal of Biological Chemistry, 2013, 288, 31299-31312.	3.4	20
81	Nano-engineered titanium for enhanced bone therapy. Proceedings of SPIE, 2013, , .	0.8	17
82	Novel Targets of Vitamin D Activity in Bone: Action of the Vitamin D Receptor in Osteoblasts, Osteocytes and Osteoclasts. Current Drug Targets, 2013, 14, 1683-1688.	2.1	21
83	Mammals and minerals: a story of lactation and lacunae. IBMS BoneKEy, 2012, 9, .	0.0	0
84	A Bioinformatics Resource for TWEAK-Fn14 Signaling Pathway. Journal of Signal Transduction, 2012, 2012, 1-10.	2.0	24
85	Osteocyte regulation of bone mineral: a little give and take. Osteoporosis International, 2012, 23, 2067-2079.	3.1	148
86	Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomaterialia, 2012, 8, 3104-3112.	8.3	20
87	Characterization of drug-release kinetics in trabecular bone from titania nanotube implants. International Journal of Nanomedicine, 2012, 7, 4883.	6.7	32
88	Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion. Acta Biomaterialia, 2012, 8, 449-456.	8.3	251
89	TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R51.	3.5	40
90	Vitamin D metabolism within bone cells: Effects on bone structure and strength. Molecular and Cellular Endocrinology, 2011, 347, 42-47.	3.2	51

#	Article	IF	CITATIONS
91	Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway. PLoS ONE, 2011, 6, e25900.	2.5	419
92	Relationship between serum RANKL and RANKL in bone. Osteoporosis International, 2011, 22, 2597-2602.	3.1	62
93	Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. Journal of Bone and Mineral Research, 2011, 26, 1425-1436.	2.8	209
94	An update on primary hip osteoarthritis including altered Wnt and TGF-Â associated gene expression from the bony component of the disease. Rheumatology, 2011, 50, 2166-2175.	1.9	16
95	Target Genes. , 2011, , 411-424.		16
96	TWEAK and TNF Regulation of Sclerostin: A Novel Pathway for the Regulation of Bone Remodelling. Advances in Experimental Medicine and Biology, 2011, 691, 337-348.	1.6	15
97	Role of polyethylene particles in peri-prosthetic osteolysis: A review. World Journal of Orthopedics, 2011, 2, 93.	1.8	44
98	Enhanced Expression of Osteocalcin mRNA in Human Osteoarthritic Trabecular Bone of the Proximal Femur Is Associated with Decreased Expression of Interleukin-6 and Interleukin-11 mRNA. Journal of Bone and Mineral Research, 2010, 15, 332-341.	2.8	44
99	Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors. Journal of Bone and Mineral Research, 2010, 15, 640-649.	2.8	168
100	Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 2010, 150, 373-376.	2.5	5
101	Osteoclastic Metabolism of 25(OH)-Vitamin D3: A Potential Mechanism for Optimization of Bone Resorption. Endocrinology, 2010, 151, 4613-4625.	2.8	127
102	The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 277-280.	2.5	63
103	Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma. Clinical Cancer Research, 2009, 15, 1998-2009.	7.0	32
104	Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by \hat{I}^3 -carboxylation-dependent and -independent mechanisms. American Journal of Physiology - Cell Physiology, 2009, 297, C1358-C1367.	4.6	108
105	The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. Journal of Bone and Mineral Metabolism, 2009, 27, 114-119.	2.7	55
106	Biomimetic hydroxyapatite coating on glass coverslips for the assay of osteoclast activity inÂvitro. Journal of Materials Science: Materials in Medicine, 2009, 20, 1467-1473.	3.6	15
107	Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporosis International, 2009, 20, 653-664.	3.1	169
108	The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials, 2009, 30, 3672-3681.	11.4	96

#	Article	IF	Citations
109	Pro-Inflammatory Cytokines TNF-Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen-Activated Protein Kinase (MAPK)-Dependent Expression of Sclerostin in Human Osteoblasts. Journal of Bone and Mineral Research, 2009, 24, 1434-1449.	2.8	161
110	Primary human osteoblasts grow into porous tantalum and maintain an osteoblastic phenotype. Journal of Biomedical Materials Research - Part A, 2008, 84A, 691-701.	4.0	78
111	Calcitonin Receptor Plays a Physiological Role to Protect Against Hypercalcemia in Mice. Journal of Bone and Mineral Research, 2008, 23, 1182-1193.	2.8	76
112	Bril: A Novel Bone-Specific Modulator of Mineralization. Journal of Bone and Mineral Research, 2008, 23, 1497-1508.	2.8	128
113	The skeleton as an intracrine organ for vitamin D metabolism. Molecular Aspects of Medicine, 2008, 29, 397-406.	6.4	82
114	Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?. Blood, 2008, 111, 5411-5412.	1.4	18
115	Metabolism of vitamin D3 in human osteoblasts: Evidence for autocrine and paracrine activities of $1\hat{i}\pm,25$ -dihydroxyvitamin D3. Bone, 2007, 40, 1517-1528.	2.9	229
116	RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)2D3 synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 601-605.	2.5	41
117	RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone. Journal of Bone and Mineral Research, 2006, 21, 1339-1349.	2.8	120
118	The correlation of RANK, RANKL and TNF \hat{l}_{\pm} expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials, 2006, 27, 5212-5219.	11.4	114
119	TWEAK Is a Novel Arthritogenic Mediator. Journal of Immunology, 2006, 177, 2610-2620.	0.8	141
120	Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Journal of Cellular Physiology, 2005, 203, 573-582.	4.1	34
121	Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology, 2005, 204, 714-723.	4.1	141
122	Target Genes: Bone Proteins. , 2005, , 711-720.		3
123	Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor κB. American Journal of Pathology, 2005, 167, 117-128.	3.8	124
124	The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials, 2004, 25, 2215-2227.	11.4	179
125	The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone, 2004, 34, 112-123.	2.9	104
126	Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone, 2004, 35, 334-342.	2.9	68

#	Article	IF	CITATIONS
127	Isolation of a Human Homolog of Osteoclast Inhibitory Lectin That Inhibits the Formation and Function of Osteoclasts. Journal of Bone and Mineral Research, 2003, 19, 89-99.	2.8	41
128	RANKL Expression Is Related to the Differentiation State of Human Osteoblasts. Journal of Bone and Mineral Research, 2003, 18, 1088-1098.	2.8	213
129	Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. British Journal of Cancer, 2003, 89, 206-214.	6.4	61
130	Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 2003, 63, 5438-45.	0.9	177
131	Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism. Journal of Endocrinology, 2002, 175, 715-725.	2.6	19
132	Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone, 2002, 31, 448-456.	2.9	66
133	Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail-induced apoptosis. International Journal of Cancer, 2002, 99, 491-504.	5.1	136
134	Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 2001, 28, 370-377.	2.9	99
135	Expression of Defensin Antimicrobial Peptides in the Peritoneal Cavity of Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2001, 21, 501-508.	2.3	13
136	The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor ^{îº} B Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis. Journal of Bone and Mineral Research, 2001, 16, 1015-1027.	2.8	123
137	The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. Journal of Bone and Joint Surgery: British Volume, 2001, 83, 902-911.	3.4	143
138	Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone, 2000, 26, 653-661.	2.9	77
139	Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells. Bone, 2000, 27, 61-67.	2.9	57
140	Calcitonin Receptor-Mediated Growth Suppression of HEK-293 Cells Is Accompanied by Induction of p21WAF1/CIP1 and G2/M Arrest. Molecular Endocrinology, 1999, 13, 1738-1750.	3.7	34
141	Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone, 1999, 25, 269-278.	2.9	45
142	Hepatitis B virus binding to leucocyte plasma membranes utilizes a different region of the preS1 domain to the hepatocyte receptor binding site and does not require receptors for opsonins. Immunology and Cell Biology, 1997, 75, 259-266.	2.3	2